Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
OCS-01- Dexamethasone Cyclodextrin Nanoparticle 1.5% mg/mL · 1 trial · 2 indications
| Name | Type | Description |
|---|---|---|
| OCS-01 - Dexamethasone Cyclodextrin Nanoparticle Ophthalmic Suspension 1.5% mg/mL | DRUG | OCS-01 eye drops |
| Placebo | DRUG | Vehicle eye drops |
OCS-01 is an investigational ophthalmic formulation of dexamethasone, a small molecule corticosteroid, prepared as a cyclodextrin nanoparticle suspension at 1.5% mg/mL. It is being developed by Oculis Holding AG for corneal inflammation and related eye conditions. It is in Phase 2 clinical development.
OCS-01 is being studied for corneal inflammation. Its completed Phase 2 trial also evaluated it in postoperative pain following cataract surgery. The drug remains investigational and has not been approved for any indication.
OCS-01 is being developed by Oculis Holding AG, which trades under the ticker OCS. The company is the sponsor of the clinical program for this dexamethasone cyclodextrin nanoparticle ophthalmic suspension.
OCS-01 is in Phase 2 clinical development. One Phase 2 trial has been completed, and no trials are currently active. The drug is investigational and has not received regulatory approval.
OCS-01 has been evaluated in one completed Phase 2 trial, NCT04130802, titled OCS-01 in Treating Inflammation and Pain in Post-cataract Patients. The trial enrolled 153 participants and studied corneal inflammation and postoperative pain. It was an uncontrolled study.